PRiZM+: A phase 1 trial of zanubrutinib in people with relapsed or refractory primary central nervous system lymphoma

This trial is testing zanubrutinib in people with relapsed or refractory primary central nervous system (CNS) lymphoma.

You can share the following IRSCTN.com identifier with your medical team so they can find out more about the trial: ISRCTN90634455

Trial aim and background

The aim of this trial is to find out how well zanubrutinib works for primary CNS lymphoma, as well as its impact on the body and potential side effects.

This is a registration trial, so if you take part, you will receive zanubrutinib which is a tablet that you can take at home.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Patients over 16 with primary CNS lymphoma which has come back after (relapsed) or not responded to (refractory) treatment may be eligible for this trial

Locations

Recruitment is taking place in the following UK locations:

Aberdeen
Belfast
Glasgow
Leeds
Liverpool
London
Manchester
Newcastle upon Tyne
Nottingham
Oxford
Plymouth
Southampton

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.isrctn.com/ISRCTN90634455

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.